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Sphingolipids are constituents of cellular membranes and play important roles as second 2 
messengers mediating cell functions.  As significant components in foods, sphingolipids have 3 
been proven to be critical for human health.  Moreover, diverse metabolic intermediates of 4 
sphingolipids are known to play key roles both in proinflammatory and in anti-inflammatory 5 
effects.  However, the effect of dietary sphingolipids on inflammation is a complicated field that 6 
needs to be further assessed.  Our study evaluated the effects of orally administered maize 7 
glucosylceramide (GluCer), one of the most conventional dietary sphingolipids, on inflammation 8 
using the 2, 4-dinitro-1-fluorobenzene (DNFB)-treated BALB/c murine model.  Oral 9 
administration of GluCer inhibited ear swelling and leukocyte infiltration to the inflammatory 10 
site, suggesting that dietary GluCer has anti-inflammatory properties.  ELISA analyses revealed 11 
that oral administration of GluCer for 6 days was not modified the Th1/Th2 balance, but 12 
significantly down-regulated the activation of TNF-α at the inflammatory site.  Based on these 13 
results, the down-regulation of TNF-α by dietary GluCer may suppress vascular permeability and 14 
reduce the migration of inflammatory cells.  Our findings increase understanding of the actions 15 
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DNFB 2, 4-dinitro-1-fluorobenzene 7 
GluCer glucosylceramide  8 
IFN-γ interferon-gamma  9 
IgE immunoglobulin E 10 
IL-1β interleukin-1beta  11 
IL-4 interleukin-4 12 
IL-6 interleukin-6 13 
NF-κB receptor activator of nuclear factor-kappa B 14 
Th1 T-helper 1 15 
Th2 T-helper 2 16 





Sphingolipids are commonly believed to protect the cell surface against harmful 2 
environmental factors by forming the mechanically stable and chemically resistant outer leaflet 3 
of the plasma membrane lipid bilayer [1-4].  Sphingolipids generate diverse metabolic 4 
intermediates, notably ceramide, sphingosine, sphingosine-1-phosphate and 5 
ceramide-1-phosphate, which serve as important mediators in the signaling cascades involved in 6 
apoptosis, proliferation, and stress responses [5-8].  Although we have already demonstrated 7 
that dietary sphingolipids are poorly absorbed by the intestine [9], sphingolipids that are 8 
significant components of foods have gained considerable attention for their potential and 9 
essential roles in human health [10-14].  It has been reported that dietary supplementation with 10 
sphingolipids has diverse physiological effects, such as lowering plasma lipids [15], improving 11 
skin barrier function [16], preventing melanin formation [17], contributing to central nervous 12 
system myelination [18] as well as protecting the colon against inflammation [19-25].  However, 13 
the functional, regulatory, and physiological significance of the immune regulating effects of 14 
dietary sphingolipids is an appreciably complicated field that is not well understood.  15 
One hypothesis of immune regulation involves the balance between T-helper 1 (Th1) and 16 
T-helper 2 (Th2) cells, which direct different immune response pathways.  Th1 cells drive the 17 
"cellular immunity" pathway to fight viruses and other intracellular pathogens, eliminate cancer 18 
cells, and stimulate delayed-type hypersensitivity skin reactions.  Th2 cells are involved in 19 
"humoral immunity" and up-regulate antibody production to fight extracellular organisms.  20 
Either pathway can down-regulate the other.  Disruption of the Th1/Th2 balance can cause 21 
immunological diseases [26, 27].  Via the actions of sphingolipid degrading enzymes, such as 22 
sphingomyelinase, glycoceramidases and ceramidase, dietary sphingolipids are hydrolyzed to 23 
various kinds of metabolic intermediates which are critical for the activation and mediation of 24 
various types of immune cells.  Metabolites of sphingolipids initiate and maintain diverse 25 
aspects of immune cell balance and functional responses by regulating cell migration and 26 
inflammatory pathways [8, 20, 28-31].  For instance, sphingolipid hydrolysis products regulate 27 
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cyclooxygenase-2, interleukin 1β (IL-1β), interleukin 6 (IL-6), tumor necrosis factor α (TNF-α) 1 
and nuclear factor kappa B (NF-κB) via the sphingosine kinase 1/ sphingosine-1-phosphate and 2 
ceramide kinase 1/ceramide-1-phosphate pathways, and thus cause the activation of mast cells, 3 
control thymocyte maturation and regulate the balance of lymphocyte subpopulations [32-37].   4 
The goal of this study was to evaluate the effects of orally administered glucosylceramide 5 
(GluCer), one of the most important dietary sphingolipids, against DNFB-induced ear swelling in 6 
the BALB/c murine model, to provide further understanding of how dietary sphingolipids act on 7 
the balance between proinflammatory and anti-inflammatory responses. 8 
 9 
Materials and Methods 10 
Maize GluCer preparation 11 
GluCer from maize was kindly donated by Nippon Flour Mills Co. Ltd. (Atsugi, Japan).  12 
The purity of this GluCer was 96%, which was determined by HPLC equipped with an 13 
evaporative light-scattering detector, as described previously [12]. 14 
 15 
Animals 16 
Female BALB/c mice (6 weeks old, 15–20 g body weight) were purchased from Japan 17 
SLC Inc. (Shizuoka, Japan).  Animals were group-housed at 6 mice per cage, and were bred at 18 
the Institute's animal facilities at 25 °C with a 12-hour light/dark cycle.  Pure water and 19 
AIN-93G diet (Oriental Yeast Co., LTD., Tokyo, Japan) were available ad libitum.  All 20 
experiments were performed according to the guidelines of Kyoto University for the use and care 21 
of laboratory animals.  22 
 23 
Contact hypersensitivity induced by DNFB 24 
After a 2-week acclimatization period, allergic contact dermatitis was induced by DNFB in 25 
BALB/c mice according to a previously published method with minor modifications [38].  26 
Briefly, mice were sensitized on day 0 by application of 100 µl 0.5% DNFB in acetone-soybean 27 
oil (4:1, v/v) on their shaved dorsal skin.  The mice were divided into control, low dose (5 mg) 28 
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and high dose (50 mg) groups (n=12 in each group).  An identifying mark was made on the tail 1 
of each mouse.   2 
The maize GluCer was suspended in 0.5% carboxymethyl cellulose (CMC) (Nacalai 3 
Tesque Co. Ltd., Kyoto, Japan) solution and was orally administered at 5 or 50 mg to each 4 
mouse daily for six days.  One hour after the final treatment, mice were challenged with 20 µL 5 
0.5% DNFB in acetone–soybean oil (4:1) on both ears.  The thickness of the right ear of each 6 
mouse was measured with a Dial Thickness Gauge (Mitutoyo Co., Kanagawa, Japan) at 0, 6 and 7 
24 hours after the DNFB challenge.  Ear swelling was calculated as the difference in thickness 8 
before and after challenge [39]. 9 
Six hours (n=6) and 24 hours (n=6) after DNFB treatment, blood was collected and mice 10 
were sacrificed under anesthesia.  The right ear and spleen of each mouse was immediately 11 
excised and frozen in liquid nitrogen, then stored at -80°C until use.   12 
 13 
Morphological analysis  14 
The left ear of each mouse was fixed in 10% neutral buffered formalin solution and was 15 
then processed routinely into paraffin wax.  Formalin fixed paraffin sections were stained with 16 
hematoxylin and eosin (H&E) to observe morphological changes using a microscope (Keyence 17 
Co., Osaka, Japan).  18 
 19 
Measurement of cytokine production and serum immunoglobulin E (IgE) 20 
Amounts of IFN-γ, interleukin-4 (IL-4), TNF-α and interleukin-10 (IL-10) in homogenates 21 
of tissues were quantified using Murine IL-4 (Diaclone Research, Besancon, France), Murine 22 
IFN-γ (Diaclone Research),  Mouse TNF-α (Pierce Biotechnology Inc., Rockford, IL, USA),  23 
and Murine IL-10 (Diaclone Research) ELISA kits, respectively, according to the manufacturer’s 24 
instructions.  Levels of those cytokines in each supernatant were normalized to total protein 25 
content, which was determined using a DC Protein assay kit (Bio-Rad Laboratories, Hercules, 26 
CA, USA).  Total serum IgE levels of DNFB-challenged mice were quantified using a Mouse 27 
IgE ELISA kit (Immunology Consultants Laboratory, Newberg, Oregon, USA) according to the 28 
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manufacturer’s instructions. 1 
 2 
Statistical analysis 3 
Data are reported as means ± SD.  Statistical analyses were performed using one-way 4 
analysis of variance (ANOVA) with Fisher's PLSD method to identify levels of significance 5 
between the groups. 6 
 7 
Results  8 
GluCer suppresses DNFB-induced ear swelling of BALB/c mice 9 
After challenge with DNFB, typical allergic contact dermatitis was provoked in ears of 10 
BALB/c mice, which was characterized by an initial increase of ear thickness and visible 11 
congestion of blood vessels.  Oral treatment with maize GluCer suppressed DNFB-induced 12 
inflammatory symptom (redness and thickness) of ears.  As shown in Fig. 1, a significant 13 
depression of ear thickness was observed at 6 h in both low (5mg/day) and high dose (50mg/day) 14 
GluCer treated groups (p<0.05).  At 24 h, the average value of ear thickness was also reduced 15 
by GluCer, but there were no statistical differences among the three groups, which may due to 16 
large individual differences.  The reduction of DNFB-induced ear swelling implies dietary 17 
GluCer has anti-inflammatory property. 18 
 19 
GluCer inhibits inflammatory infiltrates in the ears of BALB/c mice 20 
Histological specimens of ears were prepared at 6 h and 24 h after topical application of 21 
DNFB in BALB/c mice.  In the control group, typical allergic contact dermatitis with congested 22 
blood vessels and apparent edema could be observed by H&E staining.  As shown in Fig. 2A 23 
and Fig. 2D, microvascular dilations and dense leukocytes infiltrating the connective tissue, 24 
which are characteristics of inflammatory reactions, were clearly observed in the control group.  25 
At higher magnification, various kinds of migrated inflammatory cells could also be observed, 26 
including fibrocytes, mononuclear cells, degranulated mast cells and other leukocytes.  These 27 
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results confirm that DNFB induces severe inflammation in the ears of BALB/c mice and that a 1 
variety of lymphocytes migrated out from blood vessels during this contact sensitivity procedure.  2 
In both the low (5 mg/day) and the high (50 mg/day) dose GluCer-treated groups, microvascular 3 
dilation and leukocytes in inflammatory infiltrates were inhibited at 6 h (Fig. 2 B&C) and 24 h 4 
groups (Fig. 2 E&F).  These results show that dietary GluCer inhibits microvascular dilation 5 
and inflammatory infiltration of DNFB-induced BALB/c mice. 6 
 7 
GluCer inhibits inflammation by reducing TNF-α production in the ear 8 
To clarify the effect of GluCer on DNFB-induced inflammation, especially on Th1/Th2 9 
balance, levels of IFN-γ as an indicator of Th1 cells and IL-4 as an indicator of Th2 cells were 10 
measured by ELISA assay.  IFN-γ and IL-4 levels of GluCer-treated group were not 11 
significantly altered (Table 1).  In other words, Th1/Th2 balance was not modified by oral 12 
administration of GluCer for 6 days. 13 
For further evaluating the effect of GluCer on DNFB-induced inflammation, IL-10 was 14 
determined.  In ear, IL-10 was significantly decreased at 6 h both low and high dose groups, 15 
whereas this effect did not prolong to 24 h (Table 1).  However, in spleen, IL-10 was increased 16 
by GluCer treatment at 24 h, but not reached a statistical significance in 6 h because of the 17 
relatively large individual differences (Table 1).  18 
TNF-α as the most important proinflammatory cytokine and IgE as the most important 19 
antibody in the serum were also measured.  As shown in Fig. 3A, the TNF-α level in the ear 20 
was significantly suppressed both in the low and high dose GluCer groups (p<0.05).  Moreover, 21 
TNF-α level was also significantly down-regulated at 24 h by the effect of high dose GluCer (Fig. 22 
3B).   In contrast, IgE in the serum was almost at the same level among the control, low and 23 
high GluCer dose groups (Fig. 3 C&D).  The anti-inflammatory effect of dietary GluCer on 24 
contact dermatitis in DNFB-induced BALB/c mice is via regulation of the level of TNF-α 25 





The findings presented here indicate that dietary plant GluCer, one of the most important 1 
and abundant sphingolipids in food [12], suppresses the DNFB-induced ear swelling of BALB/c 2 
mice, and inhibits the microvascular dilation and inflammatory infiltration response via 3 
down-regulating levels of TNF-α, but not modifying the balance of Th1/Th2.  Meanwhile, 4 
over-expressed IL-10 in inflammatory ear skin was suppressed by dietary GluCer.  This 5 
anti-inflammatory effect of dietary GluCer increases our understanding of biofunctional 6 
sphingolipids.   7 
Dietary GluCer is known to be hydrolyzed to ceramide, sphingosine and free fatty acids in 8 
the intestinal lumen. In mucosal cells, exogenous free sphingosine and dihydrosphingosine are 9 
rapidly absorbed and metabolized to palmitic acid [40].  A smaller portion of the sphingoid 10 
bases is reincorporated into ceramide and more complex sphingolipids.  Our recent findings 11 
revealed that dietary GluCer originating from higher plants can be hydrolyzed in the intestine 12 
and that the intact plant form of sphingoid bases is barely absorbed by the tissues [9,41].  Ono 13 
et al. reported that dietary maize and yeast GluCer did not alter the sphingoid base composition 14 
in the skin of NC mice [42].  We speculate that dietary maize GluCer accomplishes its 15 
anti-inflammatory effect, not only by producing bio-active metabolic intermediates through the 16 
sphingolipid metabolic pathways, but also via the activation of sphingolipid metabolic enzymes 17 
that affect endogenous sphingolipids at the inflammatory site, because diverse metabolic 18 
intermediates of sphingolipids, including ceramide, sphingosine, sphingosine-1-phosphate and 19 
ceramide-1-phosphate are well known important and highly bioactive endogenous regulators, 20 
which are involved in a complex metabolism network and play critical roles in inflammation 21 
[43-46].   22 
In the case of our study, dietary maize GluCer accomplishes its inhibition of inflammation 23 
via the down-regulation of TNF-α level at the inflammatory site.  TNF-α, produced by 24 
mononuclear phagocytes and other inflammatory cells (neutrophils, lymphocytes, natural killer 25 
cells and mast cells) or non-inflammatory cells (endothelial cells), is known to be one of the 26 
most important inflammatory mediators [47,48].  TNF-α facilitates the formation of adhesion 27 
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molecules, vascular permeability and migration of leukocytes to sites of inflammation by 1 
affecting endothelial cells [49-51].  Our results reveal that dietary maize GluCer down-regulates 2 
levels of TNF-α in inflammatory ears.  This down-regulation of TNF-α may affect endothelial 3 
cells and inflammatory cells, and also can inhibit vascular permeability at the site of 4 
inflammation.  As a result, leukocyte migration is reduced.  In the inflammatory cells, DNFB 5 
activates NF-κB by depredating the inhibitor of NF-κB (IκB) [52].  In addition, it has been 6 
reported that sphingolipids down regulated TNF-α via inactivating of NF-κB in 7 
histamine-induced mouse skin tissues [53].  Thus, dietary GluCer seems to inhibit the DNFB 8 
activated NF-κB and down-modulate TNF-α expression in this study.  9 
Moreover, IL-10 levels were increased in spleens but suppressed in ears by dietary GluCer. 10 
This well known anti-inflammatory cytokine, IL-10, has been reported over-expressed during the 11 
antigen-specific type of skin inflammation [54] and DNFB-challenged ear [55, 56].  IL-10 is 12 
released by CD4+ T helper 2 (Th2) cell clones and a variety of other cells, including 13 
keratinocytes, macrophages, B lymphocytes, and mast cells [56].  The suppressive effect of 14 
dietary GluCer on IL-10 expression in DNFB-challenged ears might be caused by the inhibition 15 
of leukocytes infiltrating to inflammatory site. 16 
Ono et al. demonstrate that supplementation of 0.1% GluCer diet for 7-week prevented 17 
atopic dermatitis-like symptoms in a mouse model by regulating the Th1/Th2 balance [42].  18 
However, IFN-γ, IL-4 and IgE levels, the markers of Th1/Th2 balance, were not notably affected 19 
by GluCer administration for 6 days in the present study.  It appears that the period of treatment 20 
is important for immunological response of dietary GluCer.    21 
Furthermore, allergic inflammatory skin disease is associated with a loss of ceramide in 22 
the extracellular lamellar membranes which causes an abnormal barrier function of the stratum 23 
corneum [57].  Application of ceramide on diseased skin could significantly reduce allergic 24 
inflammatory reactions by improving the severity score, stratum corneum cohesion and 25 
hydration [58-60].  Dietary GluCer might also improve the stratum corneum cohesion and 26 
hydration of ear skin to reduce the skin inflammation.    27 
11 
 
In summary, our data provide evidence that maize GluCer has anti-inflammatory effects on 1 
the DNFB-induced inflammation of BALB/c mice.  We confirmed that dietary GluCer inhibits 2 
ear swelling and leukocyte infiltration.  Furthermore, our results indicate that this effect is 3 
accomplished mainly by down-regulating TNF-α, but does not significantly affect Th1/Th2 4 
balance or IgE levels in the serum.  We hypothesize that dietary GluCer accomplishes its 5 
anti-inflammatory effect by down-regulating TNF-α to suppress vascular permeability. This 6 
reduces the migration of inflammatory cells, affects endogenous sphingolipids through metabolic 7 
pathways by activating sphingolipid-related enzymes, and moreover, by hydrolysis to ceramide 8 
to improve skin barrier function at the dermatitis site.  Our findings increase the comprehensive 9 
understanding of the actions of dietary sphingolipids on the balance of immune responses. 10 
 11 
Acknowledgment 12 
This work was supported by the Program for Promotion of Basic and Applied Researches 13 





1. Lingwood D, Simons K (2010) Lipid rafts as a membrane-organizing principle. Science 327: 2 
46 – 50 3 
2. Bartke N, Hannun YA (2009) Bioactive sphingolipids: metabolism and function. J Lipid Res 4 
50: 91 – 96 5 
3. Prabuddha S, Barbara B, David H (2007) Lipid rafts, fluid/fluid phase separation, and their 6 
relevance to plasma membrane structure and function. Semin Cell Dev Biol 18: 583-590  7 
4. Merrill AH Jr, Schmelz EM, Dillehay DL, Spiegel S, Shayman JA, Schroeder JJ, Riley RT, 8 
Voss KA, Wang E (1997) Sphingolipids--the enigmatic lipid class: biochemistry, physiology, 9 
and pathophysiology. Toxicol Appl Pharmacol 142: 208-225 10 
5. Spiegel S, Merrill AH Jr (1996) Sphingolipid metabolism and cell growth regulation. FASEB J 11 
10: 1388-1397 12 
6. Zheng W, Kollmeyer J, Symolon H, Momin A, Munter E, Wang E, Kelly S, Allegood JC, Liu 13 
Y, Peng Q, Ramaraju H, Sullards MC, Cabot M, Merrill AH Jr (2006) Ceramides and other 14 
bioactive sphingolipid backbones in health and disease: Lipidomic analysis, metabolism and 15 
roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta 16 
1758: 1864-1884  17 
7. Nixon GF (2009) Sphingolipids in inflammation: pathological implications and potential 18 
therapeutic targets. Br J Pharmacol 158: 982-993 19 
8. El Alwani M, Wu BX, Obeid LM, Hannun YA (2006) Bioactive sphingolipids in the 20 
modulation of the inflammatory response. Pharmacol Ther 112: 171-183 21 
9. Sugawara T, Tsuduki T, Yano S, Hirose M, Duan J, Aida K, Ikeda I, Hirata T (2010) Intestinal 22 
absorption of dietary maize glucosylceramide in lymphatic duct cannulated rats. J Lipid Res 51: 23 
1761-1769 24 
10. Yunoki K, Ogawa T, Ono J, Miyashita R, Aida K, Oda Y, Ohnishi M (2008) Analysis of 25 
sphingolipid classes and their contents in meals. Biosci Biotechnol Biochem 72: 222-225  26 
11. Duan J, Sugawara T, Hirata T (2010) Sphingolipids in seafood using HPLC with evaporative 27 
13 
 
light-scattering detection: Its Application in tissue distribution of Sphingolipids in fish. J Oleo 1 
Sci 59: 509-513 2 
12. Sugawara T, Miyazawa T (1999) Separation and determination of glycolipids from edible plant 3 
sources by high performance liquid chromatography and evaporative light scattering detection. 4 
Lipids 34: 1231–1237 5 
13. Nyberg L, Duan RD, Nilsson Å (1998) Sphingomyelin- a dietary component with structural 6 
and biological function. Prog Colloid Polym Sci 108: 119-128 7 
14. Vesper H, Schmelz EM, Nikolova-Karakashian MN, Dillehay DL, Lynch DV, Merrill AH Jr 8 
(1999) Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J Nutr 9 
129: 1239–1250 10 
15. Duivenvoorden I, Voshol PJ, Rensen PC, van Duyvenvoorde W, Romijn JA, Emeis JJ, 11 
Havekes LM, Nieuwenhuizen WF (2006) Dietary sphingolipids lower plasma cholesterol and 12 
triacylglycerol and prevent liver steatosis in APOE*3Leiden mice. Am J Clin Nutr 84:312-321 13 
16. Tsuji K, Mitsutake S, Ishikawa J, Takagi Y, Akiyama M, Shimizu H, Tomiyama T, Igarashi Y 14 
(2006) Dietary glucosylceramide improves skin barrier function in hairless mice. J Dermatol 15 
Sci 44: 101—107  16 
17. Kinoshita M, Hori N, Aida K, Sugawara T, Ohnishi M (2007) Prevention of melanin formation 17 
by yeast cerebroside in B16 mouse melanoma cells. J Oleo Sci 56: 645-648 18 
18. Oshida K, Shimizu T, Takase M, Tamura Y, Shimizu T, Yamashiro Y (2003) Effects of dietary 19 
sphingomyelin on central nervous system myelination in developing rats. Pediatr Res 53: 20 
589-593  21 
19. Sugawara T, Kinoshita M, Ohnishi M, Miyazawa T (2002) Apoptosis induction by wheat-flour 22 
sphingoid bases in DLD-1 human colon cancer cells. Biosci Biotechnol Biochem 66: 23 
2228–2231  24 
20. Duan RD, Nilsson Å (2009) Metabolism of sphingolipids in the gut and its relation to 25 
inflammation and cancer development. Prog Lipid Res 48: 62-72 26 
21. Merrill AH Jr, Schmelz EM, Wang E, Schroeder JJ, Dillehay DL, Riley RT (1995) Role of 27 
14 
 
dietary sphingolipids and inhibitors of sphingolipid metabolism in cancer and other diseases. J 1 
Nutr 125: 1677–1682 2 
22. Aida K, Kinoshita M, Tanji M, Sugawara T, Tamura M, Ono J, Ueno N, Ohnishi M (2005) 3 
Prevention of aberrant crypt foci formation by dietary maize and yeast cerebrosides in 4 
1,2-dimethylhydrazine-treated mice. J Oleo Sci 54: 45-49 5 
23. Berra B, Colombo I, Sottocornola E, Giacosa A (2002) Dietary sphingolipids in colorectal 6 
cancer prevention. Eur J Cancer Prev 11: 193-197 7 
24. Sugawara T, Kinoshita M, Ohnishi M, Miyazawa T (2002) Apoptosis induction by wheat-flour 8 
sphingoid bases in DLD-1 human colon cancer cells. Biosci Biotechnol Biochem 66: 9 
2228–2231  10 
25. Kinoshita M, Aida K, Tokuji Y, Sugawara T, Ohnishi M (2009) Effects of dietary plant 11 
cerebroside on gene expression in the large intestine of 1,2-dimethylhydrazine (DMH)-treated 12 
mice determined by DNA microarray analysis. J Food Lipids 16: 200-208 13 
26. Kidd P (2003) Th1/Th2 balance: the hypothesis, its limitations, and implications for health and 14 
disease. Altern Med Rev 8: 223-246 15 
27. Hernández-Pando R, Orozcoe H, Sampieri A, Pavón L, Velasquillo C, Larriva-Sahd J, Alcocer 16 
JM, Madrid MV (1996) Correlation between the kinetics of Th1, Th2 cells and pathology in a 17 
murine model of experimental pulmonary tuberculosis. Immunology 89: 26-33 18 
28. Dinarello CA (1997) Proinflammatory and anti-inflammatory cytokines as mediators in the 19 
pathogenesis of septic shock. Chest 112: 321-329 20 
29. Lahiri S, Futerman AH (2007) The metabolism and function of sphingolipids and 21 
glycosphingolipids. Cell Mol Life Sci 64: 2270–2284 22 
30. Yopp AC, Randolph GJ, Bromberg JS (2003) Leukotrienes, sphingolipids, and leukocyte 23 
trafficking. J Immunol 171: 5-10 24 
31. Melendez AJ, Khaw AK (2002) Dichotomy of Ca2+ signals triggered by different phospholipid 25 
pathways in antigen stimulation of human mast cells. J Biol Chem 277: 17255-17262 26 
32. Jolly PS, Bektas M, Olivera A, Gonzalez-Espinosa C, Proia RL, Rivera J, Milstien S, Spiegel S 27 
15 
 
(2004) Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is 1 
required for normal mast cell degranulation and chemotaxis. J Exp Med 199: 959-970 2 
33. Snider AJ, Orr Gandy KA, Obeid LM (2010) Sphingosine kinase: Role in regulation of 3 
bioactive sphingolipid mediators in inflammation. Biochimie 92: 707-715 4 
34. Gilfillan AM, Tkaczyk C (2006) Integrated signalling pathways for mast-cell activation. Nature 5 
Rev Immunol 6: 218–230 6 
35. Allende ML, Dreier JL, Mandala S, Proia RL (2004) Expression of the sphingosine 7 
1-Phosphate Receptor, S1P1, on T-cells Controls Thymic Emigration. J Biol Chem 279: 8 
15396-15401 9 
36. Wei SH, Rosen H, Matheu MP, Sanna MG, Wang SK, Jo E, Wong CH, Parker I, Cahalan MD 10 
(2005) Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration 11 
of medullary T cells to lymphatic sinuses. Nat Immunol 6: 1228-1235. 12 
37. Olivera A, Rivera J (2005) Sphingolipids and the balancing of immune cell function: Lessons 13 
from the mast cell. J Immunol 174: 1153-1158 14 
38. Sakai S, Sugawara T, Kishi T, Yanagimoto K, Hirata T (2010) Effect of glucosamine and 15 
related compounds on the degranulation of mast cells and ear swelling induced by 16 
dinitrofluorobenzene in mice. Life Sci 86: 337-343 17 
39. Tomobe YI, Morizawa K, Tsuchida M, Hibino H, Nakano Y, Tanaka Y (2000) Dietary 18 
docosahexaenoic acid suppresses inflammation and immune responses in contact 19 
hypersensitivity reaction in mice. Lipids 35: 61-69 20 
40. Nilsson Å (1968) Metabolism of sphingomyelin in the intestinal tract of the rat. Biochim 21 
Biophys Acta 164: 575–584 22 
41. Sugawara T, Kinoshita M, Ohnishi M, Nagata J, Saito M (2003) Digestion of maize 23 
sphingolipids in rats and uptake of sphingadienine by Caco-2 cells. J Nutr 133: 2777–2782 24 
42. Ono J, Kinoshita M, Aida K, Tamura M, Ohnishi M (2010) Effects of dietary glucosylceramide 25 
on dermatitis in atopic dermatitis model mice. Eur J Lipid Sci Tech 112: 708-711 26 
43. Oskeritzian CA, Milstien S, Spiegel S (2007) Sphingosine-1-phosphate in allergic responses, 27 
16 
 
asthma and anaphylaxis. Pharmacol Ther 115: 390-399 1 
44. Ma Y, Pitson S, Hercus T, Murphy J, Lopez A, Woodcock J (2005) Sphingosine activates 2 
protein kinase A type II by a novel cAMP-independent mechanism. J Biol Chem 280: 3 
26011–26017 4 
45. Spiegel S, Milstien S (2003) Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev 5 
Mol Cell Biol 4: 397-407 6 
46. Pettus BJ, Kitatani K, Chalfant CE, Taha TA, Kawamori T, Bielawski J, Obeid LM, Hannun 7 
YA (2005) The coordination of prostaglandin E2 production by sphingosine-1-phosphate and 8 
ceramide-1-phosphate. Mol Pharmacol 68: 330-335  9 
47. Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat 10 
Rev Immunol 3: 745-756  11 
48. Tartaglia LA, Goeddel DV (1992) Two TNF receptors. Immunol Today 13: 151-153 12 
49. Oppenheim JJ (2001) Cytokines: past, present, and future. Int J Hematol 74: 3-8 13 
50. Borish LC, Steinke JW (2003) Cytokines and chemokines. J Allergy Clin Immunol 111: 14 
460-475 15 
51. Snider AJ, Orr Gandy KA, Obeid LM (2010) Sphingosine kinase: Role in regulation of 16 
bioactive sphingolipid mediators in inflammation. Biochimie 92: 707-715 17 
52. Cruz MT, Duarte CB, Gonçalo M, Figueiredo A, Carvalho AP, Lopes MC (2002) Differential 18 
activation of nuclear factor kappa B subunits in a skin dendritic cell line in response to the 19 
strong sensitizer 2,4-dinitrofluorobenzene. Arch Dermatol Res 294 : 419–425 20 
53. Ryu KR, Lee B, Lee IA, Oh S, Kim DH (2010) Anti-scratching Behavioral Effects of 21 
N-Stearoyl-phytosphingosine and 4-Hydroxysphinganine in Mice. Lipids 45: 613-618 22 
54. Inoue R, Otsuka M, Nishio A, Ushida K (2007) Primary administration of Lactobacillus 23 
johnsonii NCC533 in weaning period suppresses the elevation of proinflammatory cytokines 24 
and CD86 gene expressions in skin lesions in NC/Nga mice. FEMS Immunol Med Microbiol 25 
50: 67–76 26 
55. Fujiwara R, Sasajima N, Takemura N, Ozawa K, Nagasaka Y, Okubo T, Sahasakul Y, 27 
17 
 
Watanabe J, Sonoyama K (2010) 2,4-Dinitrofluorobenzene-Induced Contact Hypersensitivity 1 
Response in NC/Nga Mice Fed Fructo-Oligosaccharide. J Nutr Sci Vitaminol 56:260-265  2 
56. Wang M, Qin X, Mudgett JS, Ferguson TA, Senior RM, Welgus HG (1999) Matrix 3 
metalloproteinase deficiencies affect contact hypersensitivity: stromelysin-1 deficiency 4 
prevents the response and gelatinase B deficiency prolongs the response. PANS 96:6885-6889 5 
57. Snider AJ, Orr Gandy KA, Obeid LM (2010) Sphingosine kinase: Role in regulation of 6 
bioactive sphingolipid mediators in inflammation. Biochimie 92: 707-715 7 
58. Ishikawa J, Takada S, Hashizume K, Takagi Y, Hotta M, Masukawa Y, Kitahara T, Mizutani Y, 8 
Igarashi Y (2009) Dietary glucosylceramide is absorbed into the lymph and increases levels of 9 
epidermal sphingolipids. J Dermatol Sci 56: 220-222  10 
59. Proksch E, Fölster-Holst R, Jensen JM (2006) Skin barrier function, epidermal proliferation 11 
and differentiation in eczema. J Dermatol Sci 43: 159-169 12 
60. Piekutowska A, Pin D, Rème CA, Gatto H, Haftek M (2008) Effects of a topically applied 13 
preparation of epidermal lipids on the stratum corneum barrier of atopic dogs. J Comp Pathol 14 




Figure Legends 1 
 2 
Fig. 1 Effect of orally administered GluCer on DNFB-induced ear swelling in BALB/c mice.   3 
     The thickness of the left ear of each mouse was measured both before and after the DNFB 4 
challenge. Ear swelling values are presented as the difference in thickness at 6 h (A) and at 24 h 5 
(B): Ear swelling = ear thickness after challenge (6/24 h) – ear thickness before challenge (0 h).  6 
Con, 6 days 0.5% CMC (vehicle) orally administered; Low, 6 days low dose (5 mg/day) maize 7 
GluCer orally administered; High, 6 days high dose (50 mg/day) maize GluCer orally administered. 8 
Values are means ± SD, n = 6.  Values with different superscript letters are significantly different 9 
(p<0.05). 10 
 11 
Fig. 2 Histopathological analysis of orally administered maize GluCer on DNFB-induced ear 12 
swelling in BALB/c mice.  13 
     Morphological changes in the left ear of 6 h and 24 h after DNFB-challenged BALB/c mice 14 
were observed.  Ear sections from control mice (A), low dose (5 mg/day) maize GluCer 15 
administered mice (B) and high dose (50 mg/day) maize GluCer administered mice (C) were 16 
stained with hematoxylin and eosin (H&E).    Microvasular (asterisk marks) and leukocyte 17 
(arrowheads) were pointed out in the histological sections.  Sections are representatives of more 18 
than five observations. 19 
 20 
Fig. 3 TNF-α levels in the ears and IgE levels in the serum of DNFB- challenged BALB/c mice. 21 
     TNF-α (A,B) levels in the right ear homogenates and IgE levels in the serum (C,D) of 22 
control, low dose (5 mg/day) and high dose (50 mg/day) maize GluCer administered mice were 23 
measured both 6 (A,C) and 24 h (B,D) after the DNFB challenge.  These data represent the 24 
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Table 1. IFN-γ, IL-4 and IL-10 levels in ears and spleens of DNFB-challenged 
BALB/c mice. 
Cytokines 
  Ear   Spleen 
  6 h 24 h 
 
6 h 24 h 
 
mg/day pg/mg protein 
IFN-γ 
0 482.4±106.3 85.9±16.7 
 
7.6±4.9 6.8±1.7 
5 362.0±089.4 89.1±18.3 
 
7.5±4.1 8.5±2.7 





   
IL-4 
0 25.3±4.4 10.3±2.5 
 
2.8±0.9 1.9±0.4 
5 30.6±6.5 10.7±2.3 
 
4.0±1.0 1.8±0.2 





   
IL-10 
0 3137.7±881.3 a 698.7±212.5 
 
105.5±23.5 056.3±07.8 a 
5  1326.7±297.7 a,b 543.0±158.9 
 
131.0±37.9  072.0±33.1 a,b 
50 1578.5±352.3 b 618.0±264.9   170.2±47.6 110.4±48.7 b 
These data represent the means ± SD for groups of six mice. Values with different 
superscript letters in the same series differ significantly (p<0.05). 
 
